|7th January 2021||Advisors Llc Orbimed||2,000,000||Open or private sale||$3.50||$7,000,000.00|
|28th December 2020||Peter A. Thompson||600,000||Open or private sale||$14.25||$8,550,000.00|
|28th December 2020||Advisors Llc Orbimed||600,000||Open or private sale||$14.25||$8,550,000.00|
|8th December 2020||Advisors Llc Orbimed||952,377||Open or private purchase||$21.00||$19,999,917.00|
|8th December 2020||Advisors Llc Orbimed||1,055,287||Conversion of derivative||$0.00|
|8th December 2020||Advisors Llc Orbimed||21,400||Open or private sale||$1.96||$41,944.00|
|8th December 2020||Peter A. Thompson||238,100||Open or private purchase||$21.00||$5,000,100.00|
|8th December 2020||Advisors Llc Orbimed||21,400||Exercise of in-the-money or at-the-money derivatives securities (usually options)||$0.96||$20,544.00|
|8th December 2020||Advisors Llc Orbimed||3,462,737||Conversion of derivative||$0.00|
|8th December 2020||Advisors Llc Orbimed||2,493,741||Conversion of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Corvus Pharmaceuticals, Inc. engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444.